Evidence map›Paper›PMID 41768642›Full record

ArticleACS omega2026

Benchmarking the Ligand-HER2 Interactions Using Machine Learning and Molecular Dynamics Simulations.

Duc Toan Truong, Quang Tung Dao, Thi Thuy Mai Tran, Ngoc Ha Nguyen, My-Kristyna Nguyen-Thao, Nguyen-Hai Nam, Thi Mai Dung Do, Minh Tho Nguyen

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Duc Toan TruongLaboratory for Chemical Computation and Modeling, Institute for Computational Science and Artificial Intelligence, Van Lang University, Ho Chi Minh City 70000, Vietnam.
Quang Tung DaoDepartment of Computer and System Sciences, Stockholm University, SE-106 91 Stockholm, Sweden.
Thi Thuy Mai TranFaculty of Pharmaceutical Chemistry and Technology, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Cua Nam, Hanoi 10000, Vietnam.
Ngoc Ha NguyenFaculty of Pharmaceutical Chemistry and Technology, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Cua Nam, Hanoi 10000, Vietnam.
My-Kristyna Nguyen-ThaoFaculty of Pharmaceutical Chemistry and Technology, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Cua Nam, Hanoi 10000, Vietnam.
Nguyen-Hai NamFaculty of Pharmaceutical Chemistry and Technology, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Cua Nam, Hanoi 10000, Vietnam.
Thi Mai Dung DoFaculty of Pharmaceutical Chemistry and Technology, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Cua Nam, Hanoi 10000, Vietnam.ORCID https://orcid.org/0000-0003-3326-2464
Minh Tho NguyenCenter for Environmental Intelligence, VinUniversity, Gia Lam, Hanoi 10000, Vietnam.ORCID https://orcid.org/0000-0002-3803-0569

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the inhibitor-HER2 interaction mechanism remains a critical challenge in combating breast cancer. In the present work, the role of five critical residues that are deeply located in the HER2 active site was recognized. To win the race against time in learning the activities of the HER2 tyrosine kinase protein, we employed a stepwise computational procedure including a machine learning predictive regression model, atomistic molecular dynamics (MD) simulations, and the umbrella sampling MD method. A systematic mining of a data set of 8 million chemical compounds allowed us to finally identify 13 candidates whose capacities as anti-HER2 have not been reported before. Based on the computed results, a benchmark for the strength of the ligand-HER2 interaction has been established. Although van der Waals potential energy tends to stabilize ligand-protein associations, the ligand that electrostatically interacts with five residues, Lys753, Leu796, Thr798, Asp863, and Asp880, is a key factor in deciding the inhibitor strength. Significantly, the strong binding of compound lig233 was exemplified by its ability to form hydrogen bonds with Asp863 and Asp880 and maintain exceptionally short distances to many key residues, indicating the formation of strong chemical bonds. Lig233 also exhibits a binding free energy of -47 kcal/mol, two times as large as that of -21 kcal/mol for the known drug lapatinib. The fresh understanding achieved in the present study can lead to the necessary adjustments in the experimental development of HER2 inhibitors.

Identifiers

PMID41768642
PMCPMC12947145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.